Q2 EPS Estimates for Palisade Bio Raised by Analyst

Palisade Bio, Inc. (NASDAQ:PALI) – Equities researchers at Brookline Capital Markets boosted their Q2 2026 earnings estimates for shares of Palisade Bio in a research report issued on Wednesday, May 20th. Brookline Capital Markets analyst K. Raja now expects that the company will earn ($0.05) per share for the quarter, up from their prior estimate of ($0.06). The consensus estimate for Palisade Bio’s current full-year earnings is ($0.22) per share. Brookline Capital Markets also issued estimates for Palisade Bio’s Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.21) EPS, FY2028 earnings at ($0.25) EPS and FY2029 earnings at ($0.35) EPS.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

Other equities research analysts also recently issued reports about the company. Stifel Nicolaus initiated coverage on Palisade Bio in a report on Wednesday, February 25th. They set a “buy” rating and a $5.00 target price on the stock. HC Wainwright initiated coverage on shares of Palisade Bio in a research report on Thursday, March 26th. They issued a “buy” rating and a $7.00 price objective for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Wolfe Research initiated coverage on shares of Palisade Bio in a research note on Thursday, April 9th. They issued an “outperform” rating and a $7.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.20.

Palisade Bio Price Performance

Shares of NASDAQ PALI opened at $2.01 on Friday. Palisade Bio has a 1-year low of $0.53 and a 1-year high of $2.86. The company has a market capitalization of $348.90 million, a price-to-earnings ratio of -1.99 and a beta of 1.52. The business has a 50-day moving average of $2.00 and a 200-day moving average of $1.92.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in PALI. Total Clarity Wealth Management Inc. acquired a new stake in shares of Palisade Bio during the 4th quarter valued at approximately $70,000. Jefferies Financial Group Inc. acquired a new position in Palisade Bio in the fourth quarter worth $110,000. Geode Capital Management LLC increased its stake in Palisade Bio by 5,780.7% during the fourth quarter. Geode Capital Management LLC now owns 1,565,452 shares of the company’s stock valued at $3,681,000 after purchasing an additional 1,538,832 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Palisade Bio during the fourth quarter worth $1,310,000. Finally, TD Asset Management Inc acquired a new stake in shares of Palisade Bio during the fourth quarter worth $480,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.